Tumor-specific cytolysis by lymphocytes infiltrating human melanomas - PubMed (original) (raw)
. 1989 May 15;142(10):3714-25.
Affiliations
- PMID: 2785562
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas
S L Topalian et al. J Immunol. 1989.
Abstract
Tumor infiltrating lymphocytes (TIL) were grown in IL-2 from single cell tumor suspensions of 14 human melanomas resected from 12 patients. As a function of time in culture, 4 of 14 TIL cultures eventually expressed highly specific cytolytic activity against fresh autologous melanoma targets in short term chromium release assays, failing to lyse multiple allogeneic tumors or autologous normal cells. These highly specific TIL were identified as CTL by phenotype (CD3+/CD4-/CD8+/Leu7-) and by function (lysis inhibited by antibodies directed against CD3 and MHC class I molecules). Cell separation experiments using immunomagnetic beads identified a highly tumor-specific CTL subpopulation within a nonspecific TIL culture, suggesting that the lytic activity of tumor-specific CTL may be diluted by the nonspecific killer activity present in heterogeneous TIL cultures. These studies provide evidence for specific MHC-restricted human immune responses against autologous tumor in cancer-bearing patients, and may be of importance to ongoing clinical trials using TIL in the immunotherapy of advanced malignancies.
Similar articles
- Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL. Wong JT, et al. J Immunol. 1989 Nov 15;143(10):3404-11. J Immunol. 1989. PMID: 2509557 - Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA. Hom SS, et al. J Immunother (1991). 1991 Jun;10(3):153-64. J Immunother (1991). 1991. PMID: 1868040 - Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K, Tilden AB, Balch CM. Itoh K, et al. Cancer Res. 1986 Jun;46(6):3011-7. Cancer Res. 1986. PMID: 3486040
Cited by
- Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer.
Plaugher DR, Childress AR, Gosser CM, Esoe DP, Naughton KJ, Hao Z, Brainson CF. Plaugher DR, et al. Cancer Lett. 2024 Nov 28;605:217281. doi: 10.1016/j.canlet.2024.217281. Epub 2024 Oct 5. Cancer Lett. 2024. PMID: 39369769 Review. - Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells.
Tchelougou D, Malaquin N, Cardin GB, Desmul J, Turcotte S, Rodier F. Tchelougou D, et al. Front Cell Dev Biol. 2024 Jun 14;12:1368711. doi: 10.3389/fcell.2024.1368711. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38946802 Free PMC article. - GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC.
Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M, Dondaine L, Ballot E, Truntzer C, Boidot R, Hermetet F, Derangère V, Bruchard M, Végran F, Chouchane L, Ghiringhelli F, Bettaieb A, Paul C. Mabrouk N, et al. Cancers (Basel). 2023 Jun 9;15(12):3129. doi: 10.3390/cancers15123129. Cancers (Basel). 2023. PMID: 37370739 Free PMC article. - Antigen-specific and cross-reactive T cells in protection and disease.
Jiang N, Malone M, Chizari S. Jiang N, et al. Immunol Rev. 2023 Jul;316(1):120-135. doi: 10.1111/imr.13217. Epub 2023 May 20. Immunol Rev. 2023. PMID: 37209375 Free PMC article. Review. - Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects.
Modur V, Muhammad B, Yang JQ, Zheng Y, Komurov K, Guo F. Modur V, et al. Cell Rep. 2023 Apr 25;42(4):112364. doi: 10.1016/j.celrep.2023.112364. Epub 2023 Apr 10. Cell Rep. 2023. PMID: 37043352 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials